Non-Targeted Metabolomics Reveal Apomorphine's Therapeutic Effects and Lysophospholipid Alterations in Steatohepatitis

• Autori principali: Hideo Ogiso (Autore), Kouichi Miura (Autore), Ryozo Nagai (Autore), Hitoshi Osaka (Autore), Kenichi Aizawa (Autore)
• Natura: Libro
• Pubblicazione: MDPI AG, 2024-10-01T00:00:00Z.
• Soggetti: article
• Accesso online: Connect to this object online.

Metabolic dysfunction-associated steatohepatitis (MASH), characterized by progressive inflammation and fibrosis, evolves from metabolic dysfunction-associated steatotic liver disease and significantly heightens the risk of cirrhosis and hepatocellular carcinoma. Understanding metabolic pathways that...